LCTXHIGH SIGNALFINANCIAL10-K

LCTX experienced severe financial deterioration with net losses ballooning 241% to $63.5M while stockholders' equity collapsed 43% and total liabilities nearly doubled.

The dramatic increase in losses coupled with the destruction of shareholder value and doubling of liabilities suggests the company is burning through capital at an unsustainable rate. The added language about needing "substantial additional capital" and potential dilution to shareholders confirms management's concern about the company's financial runway and ability to fund operations.

Comparing 2026-03-05 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

LCTX's financial position deteriorated significantly with net losses exploding from $18.6M to $63.5M despite revenue growing 53% to $14.6M, indicating severe operational inefficiency as gross profit declined 40.8%. The balance sheet shows distress with stockholders' equity plummeting 43% to $44.5M while total liabilities nearly doubled to $69.2M, and inventory was almost completely depleted (down 99.6%). This pattern suggests a company rapidly burning cash with deteriorating unit economics and a weakening financial foundation that may require immediate capital infusion to continue operations.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-241.4%
-$18.6M-$63.5M

Net income declined 241.4% — review whether driven by operations, interest costs, or non-recurring items.

Inventory
Balance Sheet
-99.6%
$266K$1K

Inventory drawn down 99.6% — strong sell-through or deliberate destocking; watch for supply constraints.

Total Liabilities
Balance Sheet
+91.2%
$36.2M$69.2M

Liabilities grew 91.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Operating Income
P&L
-70.5%
-$21.5M-$36.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
+53.2%
$9.5M$14.6M

Strong top-line growth of 53.2% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-43.2%
$78.4M$44.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
+42.2%
$12.5M$17.7M

R&D investment increased 42.2% — signals commitment to future product development, though near-term margin impact.

Gross Profit
P&L
-40.8%
$14.0M$8.3M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Accounts Receivable
Balance Sheet
+39.7%
$638K$891K

Receivables surged 39.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Liabilities
Balance Sheet
-18.7%
$14.0M$11.4M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-10
ADDED
The number of common shares outstanding as of March 5, 2026 was 249,087,529 .
Hoffmann-La Roche Ltd and Genentech, Inc to develop and commercialize RG6501 (OpRegen).
We will continue to spend a substantial amount of our capital on research and development, but we might not succeed in developing products and technologies that are safe and effective for their target indications as determined by the U.S.
Our decisions regarding whether to advance our programs internally or through strategic relationships may not maximize the value of our pipeline for our shareholders, and misjudgments in these decisions could materially adversely affect our business.
We will need to raise substantial additional capital and capital raising transactions may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to or dilute our economic interest in our product candidates or technology.
+7 more — sign up free →
REMOVED
The number of common shares outstanding as of March 4, 2025 was 228,356,290 .
Hoffmann-La Roche Ltd and Genentech, Inc to develop and commercialize RG6501 (OpRegen ).
We will continue to spend a substantial amount of our capital on research and development, but we might not succeed in developing products and technologies that are safe and effective for their target indications or commercially viable.
We will need to raise substantial additional capital to complete the development and seek regulatory approval of our product candidates and to commercialize products approved for marketing, if any, and capital raising transactions may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to or dilute our economic interest in our product candidates or technology.
All of our manufacturing operations currently are conducted at our facility in Jerusalem, Israel, and any event or condition, such as political and economic conditions in Israel, war, terrorist attacks or other armed conflicts, that significantly disrupts our ordinary course of operations at our Jerusalem facility could harm our business and materially and adversely affect our financial condition and operating results.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →